Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单抗,一种人源抗-CD52抗体,在免耐受诱导方案中效果显著,需要最少免抑制维持药物.
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单抗,一种人源抗-CD52抗体,在免耐受诱导方案中效果显著,需要最少免抑制维持药物.
声明:以上例句、词分类均由互联网资源自动生成,部分未经过人工审核,内容亦不代本软件观点;若发现问题,欢迎向我们指正。